Switch theme
Sign up to access all valuation multiples
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
2019
53
Last FY Revenue n/a
Last FY EBITDA -$58.8M
-$33.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Third Harmonic Bio achieved revenue of n/a and an EBITDA of -$58.8M.
Third Harmonic Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Third Harmonic Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$58.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$58.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$45.5M | XXX | -$45.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Third Harmonic Bio's stock price is $5.
Third Harmonic Bio has current market cap of $235M, and EV of -$33.9M.
See Third Harmonic Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$33.9M | $235M | XXX | XXX | XXX | XXX | $-1.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Third Harmonic Bio has market cap of $235M and EV of -$33.9M.
Third Harmonic Bio's trades at n/a EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Third Harmonic Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Third Harmonic Bio has a P/E ratio of -5.2x.
See valuation multiples for Third Harmonic Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $235M | XXX | $235M | XXX | XXX | XXX |
| EV (current) | -$33.9M | XXX | -$33.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.2x | XXX | -5.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialThird Harmonic Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Third Harmonic Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Third Harmonic Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Third Harmonic Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Third Harmonic Bio acquired XXX companies to date.
Last acquisition by Third Harmonic Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Third Harmonic Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Third Harmonic Bio founded? | Third Harmonic Bio was founded in 2019. |
| Where is Third Harmonic Bio headquartered? | Third Harmonic Bio is headquartered in United States of America. |
| How many employees does Third Harmonic Bio have? | As of today, Third Harmonic Bio has 53 employees. |
| Who is the CEO of Third Harmonic Bio? | Third Harmonic Bio's CEO is Ms. Natalie C. Holles. |
| Is Third Harmonic Bio publicy listed? | Yes, Third Harmonic Bio is a public company listed on NAS. |
| What is the stock symbol of Third Harmonic Bio? | Third Harmonic Bio trades under THRD ticker. |
| When did Third Harmonic Bio go public? | Third Harmonic Bio went public in 2022. |
| Who are competitors of Third Harmonic Bio? | Similar companies to Third Harmonic Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Third Harmonic Bio? | Third Harmonic Bio's current market cap is $235M |
| Is Third Harmonic Bio profitable? | Yes, Third Harmonic Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
